Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-135 with ribavirin in treatment-naïve chronic hepatitis C
NCT01726946Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Nov 2012
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of VX-135 in hepatitis C (HCV), sponsored by Vertex Pharmaceuticals. Primary endpoint: Safety and Tolerability at 52 weeks. Started Nov 2012; status: completed.
02
Drugs
VX-135
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01726946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01726946.